SUBSCRIBE
SUBSCRIBE

Nektar Therapeutics

NEWS
Small Cambridge Biotech Warp Bio Scores $387M R&D
Business
Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
December 13, 2017
 · 
3 min read
 · 
Mark Terry
3 Biotechs That Got Huge Boosts From Spark's FDA P
BioMidwest
3 Biotech Stocks That Exploded in 2017
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year.
December 5, 2017
 · 
2 min read
 · 
Mark Terry
Gemini Therapeutics Banks $42.5M to Bring Precisio
Biotech Bay
3 Biotechs That Have Investors Grinning at Thanksgiving Dinner This Year
Investors have had a decent year, but some have much to be grateful for this Thanksgiving.
November 21, 2017
 · 
3 min read
 · 
Mark Terry
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Business
Bay Area’s Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
July 24, 2017
 · 
3 min read
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Biotech Bay
Bay Area Nektar’ Comeback is Stalled as the EMA Rejects Breast Cancer Drug
July 21, 2017
 · 
2 min read
Biotech Bay
Nektar Therapeutics: A Sweet Or Sour Investment?
June 15, 2017
 · 
1 min read
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Drug Development
For Sale: Nektar Therapeutics Plans to License Hot New Opioid Drug
March 20, 2017
 · 
3 min read
Drug Development
Nektar Therapeutics To Present At Jefferies Autumn 2015 Global Healthcare Conference In London
November 17, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Nektar Therapeutics Chief Science Officer Provides Details on Immuno-Oncology, Pain Pipelines
October 9, 2015
 · 
4 min read
Load More
AWARDS
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Drug Development
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
February 23, 2023
 · 
10 min read
Biotech Bay
Nektar Therapeutics’ President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
January 4, 2023
 · 
1 min read
Biotech Bay
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
 · 
9 min read
Biotech Bay
Nektar Therapeutics to Host Investor & Analyst Event on December 12th
December 5, 2022
 · 
5 min read
Biotech Bay
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
 · 
9 min read
Biotech Bay
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
November 9, 2022
 · 
7 min read
Business
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
November 3, 2022
 · 
14 min read
Business
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
October 25, 2022
 · 
1 min read
Biotech Bay
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
September 7, 2022
 · 
7 min read
Drug Development
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
August 16, 2022
 · 
7 min read
Load More